Who are Efgartigimod PH20 SC's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): UPLIZNA, Empasiprubart IV, IMVT-1402.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/efgartigimod-ph20-sc.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Efgartigimod PH20 SC — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efgartigimod PH20 SC (Efgartigimod PH20 SC) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: FcRn antagonist. Area: Immunology.

marketed FcRn antagonist Neonatal Fc receptor (FcRn) Immunology Biologic Live · refreshed every 30 min

Target snapshot

Efgartigimod PH20 SC (Efgartigimod PH20 SC) — argenx. Efgartigimod is an IgG Fc fragment that binds to the neonatal Fc receptor (FcRn) to reduce circulating immunoglobulin levels, particularly IgG antibodies.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Efgartigimod PH20 SC TARGET	Efgartigimod PH20 SC	argenx	marketed	FcRn antagonist	Neonatal Fc receptor (FcRn)
UPLIZNA	UPLIZNA	Amgen	marketed	FcRn antagonist	FcRn (neonatal Fc receptor)
Empasiprubart IV	Empasiprubart IV	argenx	phase 3	FcRn antagonist	FcRn (neonatal Fc receptor)
IMVT-1402	IMVT-1402	Immunovant Sciences GmbH	phase 3	FcRn antagonist	FcRn (neonatal Fc receptor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (FcRn antagonist class)

argenx · 2 drugs in this class
Amgen · 1 drug in this class
Immunovant Sciences GmbH · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Efgartigimod PH20 SC — Competitive Intelligence Brief. https://druglandscape.com/ci/efgartigimod-ph20-sc. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing